[Chapter Title]: ATX-101

[Affiliation]:

Saad Sami AlSogair
Dr Layla AlOnaizi Polyclinic, Department of Dermatology
Khobar, Eastern Province, Saudi Arabia
This email address is being protected from spambots. You need JavaScript enabled to view it.

[Introduction/ Abstract: 1 paragraph, approx. 150-250 words, don’t include reference citations or undefined abbreviations) …]

ATX-101 is an adipolytic medication that serves as a nonsurgical treatment for unwanted submental fat deposition. Sodium deoxycholate, a bile salt that occurs in the body, acts as the active ingredient in ATX-101 that treats the accumulation of localized fat through adipocytolysis. Deoxycholate disrupts the membranes of adipocytes through solubilization of the membrane lipids, leading to cell breakdown, and induces a local inflammatory response that clears the adipocyte debris. Subcutaneous injection of deoxycholate causes necrosis of the tissue as a result of its cyotoxic, detergent effects on the cellular layer. This treatment is for patients with unwanted submental fat who are frequently dissatisfied with the appearance of their face and chin. ATX-101 is injected into the underlying preplatysmal subcutaneous fat layer of the chin. The most common treatment reactions are pain, swelling, bruising, and numbness. These reactions are generally resolved in the 28-day interval between treatment sessions. Most of the adverse events with ATX-101 are mild or moderate in intensity. Injection-site pain was more commonly rated as moderate or severe but will resolve within a day. Only a few nerve injury adverse events are reported and all such events resolved without sequelae.